Literature DB >> 10338495

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

A Rudin1, G C Riise, J Holmgren.   

Abstract

Nasal vaccine delivery is superior to oral delivery in inducing specific immunoglobulin A (IgA) and IgG antibody responses in the upper respiratory tract. Although an antibody response in the nasal passages is important in protecting against primary colonization with lung pathogens, antibodies in the lungs are usually required as well. We immunized 15 male volunteers twice nasally or orally with cholera toxin B subunit (CTB) and determined the specific antibody levels in serum, bronchoalveolar lavage (BAL) fluid, and urine before and 2 weeks after immunization. Nasal immunization induced fivefold increases in the levels of specific IgA antibodies in BAL fluid of most volunteers, whereas there were no significant specific IgA responses after oral immunization. The specific IgG antibody level increased eightfold in BAL fluid in the nasally vaccinated subjects, and the major part of IgG had most probably been transferred from serum. Since the specific IgG response in serum was lower in the individuals vaccinated orally, the IgG response in BAL fluid in this group was also lower and not significant. In conclusion, nasal immunization is also preferable to the oral route when vaccinating against lower respiratory tract infections, and a systemic immune response is considerably more important in the lower than in the upper respiratory tract. Moreover, both nasal and oral immunizations were able to stimulate 6- to 10-fold specific IgA and IgG responses in urine in about half of the individuals, which indicates that distant mucosal vaccination might be used to prevent adhesion of pathogens to the urogenital tract.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338495      PMCID: PMC96596          DOI: 10.1128/IAI.67.6.2884-2890.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Reliability of cell counts and protein determinations in serial bronchoalveolar lavage procedures performed on healthy volunteers.

Authors:  D E Banks; J E Morgan; R D Deshazo; D Weissman; F H Rodriguez; H W Barkman; J E Salvaggio
Journal:  Am J Med Sci       Date:  1990-11       Impact factor: 2.378

2.  Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity.

Authors:  T Thepen; C McMenamin; J Oliver; G Kraal; P G Holt
Journal:  Eur J Immunol       Date:  1991-11       Impact factor: 5.532

Review 3.  Immunoglobulin secretion in the airways.

Authors:  R P Daniele
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

4.  Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.

Authors:  J Sanchez; J Holmgren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

5.  Comparison of pulmonary and intestinal lymphocyte migrational patterns in sheep.

Authors:  D D Joel; A D Chanana
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

Review 6.  The common mucosal immune system and current strategies for induction of immune responses in external secretions.

Authors:  J Mestecky
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

7.  Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial.

Authors:  H J Hachen
Journal:  J Urol       Date:  1990-04       Impact factor: 7.450

8.  A clonal analysis of lung T cells derived by bronchoalveolar lavage of healthy individuals.

Authors:  M J Garlepp; A H Rose; R V Bowman; N Mavaddat; J Dench; B J Holt; M Baron-Hay; P G Holt; B W Robinson
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

9.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

View more
  30 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

2.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

3.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

4.  Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.

Authors:  N Mielcarek; I Nordström; F D Menozzi; C Locht; J Holmgren
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 5.  Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly.

Authors:  Kohtaro Fujihashi; Shintaro Sato; Hiroshi Kiyono
Journal:  Exp Gerontol       Date:  2014-01-16       Impact factor: 4.032

6.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Authors:  Frederik W van Ginkel; Raymond J Jackson; Naoto Yoshino; Yukari Hagiwara; Daniel J Metzger; Terry D Connell; Hong L Vu; Michael Martin; Kohtaro Fujihashi; Jerry R McGhee
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.

Authors:  Gregory A Price; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

9.  Oral and nasal sensitization promote distinct immune responses and lung reactivity in a mouse model of peanut allergy.

Authors:  Romy Fischer; Jerry R McGhee; Huong Lan Vu; T Prescott Atkinson; Raymond J Jackson; Daniel Tomé; Prosper N Boyaka
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

10.  Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes.

Authors:  Mariana Manrique; Pamela A Kozlowski; Antonio Cobo-Molinos; Shainn-Wei Wang; Robert L Wilson; David C Montefiori; Angela Carville; Anna Aldovini
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.